A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SHR 0302 (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Sponsors Reistone Biopharma

Most Recent Events

26 Jun 2019 Planned End Date changed from 30 Jul 2020 to 30 Sep 2020.
26 Jun 2019 Planned primary completion date changed from 30 Apr 2020 to 31 Jul 2020.
14 Jun 2019 According to a Reistone Biopharma media release, first patient has been dosed in this study.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight